1260 - Correlation of CDAI and SDAI with DAS in a Large Real-Life Cohort of Rheumatoid Arthritis Patients Treated with Infliximab

Monday, November 7, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Denis Choquette, University of Montreal, Notre-dame Hospital, Montreal, QC, William G. Bensen, McMaster University, Hamilton, ON, Hamilton, ON, Milton F. Baker, VIHA, Victoria, BC, Sophie Elise Michaud, Merck Canada Inc, Montreal, QC and Hayssam Khalil, Merck Canada Inc, Kirkland, QC
Presentation Number: 1260

Background/Purpose: 

In recent years, the efficacy of anti-TNF-alpha in the management of RA has been demonstrated in numerous controlled clinical trials. The Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) have been recently designed as simplified disease activity scores. The purpose of this analysis is to evaluate the correlation between these simplified disease activity scores and routine clinical practice scores.

Method: 

The data for this analysis were obtained from an observational study of adult RA patients initiated on treatment with infliximab and followed prospectively as per routine care since 2002. The majority of patients enrolled were biologic naïve.

Result: 

A total of 440 patients were included in this analysis. Mean (SD) age was 56.4 (13.6) years and mean (SD) disease duration at baseline was 11.0 (10.2) years. Mean SDAI, CDAI, DAS28-CRP and HAQ scores decreased significantly over 48 months (p< 0.001, for all parameters). A statistically significant strong positive correlation was observed between the DAS28-CRP and the SDAI (r=0.82; p< 0.001) or CDAI (r=0.94; p< 0.001). Differences in the proportion of patients achieving low disease activity (LDA) and remission were observed between DAS28-CRP, SDAI and CDAI.

Parameter

Month 6

Month 12

Month 24

Month 36

Month 48

%

%

%

%

%

LDA (DAS 28 <3.2)

39.2

37.6

39.7

47.2

54.1

LDA (SDAI <11)

21.2

26.0

37.6

40.5

50.0

LDA (CDAI <10)

36.1

43.5

53.7

59.6

70.8

Remission (DAS 28 <2.6)

24.2

24.0

29.8

34.0

40.0

Remission (SDAI <3.3)

3.2

2.0

10.4

13.1

18.1

Remission (CDAI <2.8)

9.3

11.1

20.1

19.2

30.3

Conclusion: 

The results of this real-life observational study demonstrate that over four years of treatment infliximab is effective in reducing symptom severity and improving outcomes in patients with Rheumatoid Arthritis using different scores. Also, the data from this registry confirmed the validity of the SDAI and CDAI as disease activity measures in a real-life RA cohort.


Keywords: activity score, inflammation, infliximab, multicenter study and rheumatoid arthritis (RA)

Disclosure: D. Choquette, Merck Canada Inc, 2, Merck Canada Inc, 5 ; W. G. Bensen, none, 5 ; M. F. Baker, Merck Canada Inc, 5 ; S. E. Michaud, None; H. Khalil, Merck Pharmaceuticals, 3 .